Company Filing History:
2 out of 822 
2 out of 167 
1 out of 4,125 
Years Active: 2015
Title: **Markus Maegerlein: Innovator in Pharmaceutical Sciences**
Introduction
Markus Maegerlein is an accomplished inventor based in Mannheim, Germany, renowned for his contributions to pharmaceutical innovations. With a total of three patents to his name, he has made significant advancements in enhancing drug formulations for better therapeutic outcomes.
Latest Patents
Among his notable patents is the invention of **Crystalline Lopinavir/Surfactant Adducts**. This innovation focuses on the development of novel crystalline adducts that combine lopinavir, a key antiviral drug, with surfactants. The patent outlines methods for their preparation, therapeutic applications, and pharmaceutical compositions that utilize these adducts. Another significant patent is for **Dosage Forms with Improved Bioavailability**. This patent describes a solid dispersion product that includes active ingredients combined with hydroxypropyl methylcellulose(s). The innovative formulation aims to enhance the bioavailability of active ingredients when administered orally, thereby improving patient treatment options.
Career Highlights
Throughout his career, Markus Maegerlein has been associated with leading pharmaceutical companies, including AbbVie Inc. and AbbVie Deutschland GmbH & Co. KG. His experience in these reputable organizations has provided him with a solid foundation to innovate in the field of pharmaceutical formulations.
Collaborations
Markus has collaborated with a number of esteemed colleagues, such as Matthias Degenhardt and Geoff G. Zhang, contributing to a rich environment of innovation and development in pharmaceutical sciences. These collaborations have not only strengthened his inventions but have also played a pivotal role in the advancement of drug formulation techniques.
Conclusion
Markus Maegerlein stands out as a key inventor in the pharmaceutical industry, recognized for his innovative patents that push the boundaries of drug delivery systems. His work not only exemplifies technical excellence but also underscores the importance of collaborative efforts in the realm of scientific advancements. As the pharmaceutical landscape continues to evolve, Maegerlein's contributions will undoubtedly remain influential in improving therapeutic outcomes for patients globally.